2024
Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus
Khurana S, King L, Manischewitz J, Posadas O, Mishra A, Liu D, Beigel J, Rappuoli R, Tsang J, Golding H. Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus. Nature Medicine 2024, 1-6. PMID: 39013430, DOI: 10.1038/s41591-024-03189-y.Peer-Reviewed Original ResearchCross-neutralizing antibodiesH5N1 vaccineNeutralizing antibody responsesVaccination of adultsDevelopment of effective vaccinesGlobal public health threatHPAI H5N1Influenza virusSeroconversion ratesH5N1Neutralizing antibodiesCross-reactive bindingPublic health threatLicensed vaccinesHemagglutination inhibitionPublic health priorityAntibody responseEffective vaccineHPAIVaccineAntibodiesDoseHealth priorityVirusHealth threat
2023
Human transcriptional signature of protection after Plasmodium falciparum immunization and infectious challenge via mosquito bites
Mura M, Misganaw B, Gautam A, Robinson T, Chaudhury S, Bansal N, Martins A, Tsang J, Hammamieh R, Bergmann-Leitner E. Human transcriptional signature of protection after Plasmodium falciparum immunization and infectious challenge via mosquito bites. Human Vaccines & Immunotherapeutics 2023, 19: 2282693. PMID: 38010150, PMCID: PMC10760396, DOI: 10.1080/21645515.2023.2282693.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsNon-protected individualsHuman malaria infectionImmune correlatesMalaria infectionVaccine-induced responsesCorrelates of protectionTranscriptomic analysisBlood mononuclear cellsAntigen-specific stimulationTranscriptomic profilesAntigen-specific cellsWhole blood transcriptomic analysesImmune signaturesMalaria vaccineMononuclear cellsInfectious challengeVaccine platformEffective vaccineMosquito bitesLongitudinal time pointsSubunit vaccineInfectious pathogensTranscriptional eventsVaccine